Donate now, support IFFGD

My Cart | Register | Sign In

Header Image

Industry Treatment News

This page lists treatment news from IFFGD Industry Council Members. No endorsement is intended or implied.

What's in the news

Linaclotide (Linzess/Constella)

January 29, 2016 – Pediatric participants sought for two studies of linaclotide for treatment in children of irritable bowel syndrome with constipation, or IBS-C (ages 7–17) and for functional constipation (ages 6–17). Learn more


July 3, 2015 – Research studies suggest that nutritional therapy with SBI, the ingredient found in EnteraGam – used in addition to traditional medical care – can help manage various symptoms associated intestinal disease (enteropathy) like irritable bowel syndrome (IBS). Learn more


December 16, 2015 – Allergan has announced the availability of eluxadoline (Viberzi) by prescription in the US for the treatment of IBS-D. Learn more


May 27, 2015 – The antibiotic, rifaximin (Xifaxan), has been approved by the U.S. Food & Drug Administration (FDA) for treating patients with irritable bowel syndrome with diarrhea (IBS-D) Learn more


January 5, 2015 – The Japanese Ministry of Health, Labor, and Welfare (MHLW) granted teduglutide (Gattex in the US; Revestive in the EU) orphan drug status for the treatment of adult patients with short bowel syndrome (SBS). Learn more

CSID Genetic Prevalence Study

October 8, 2014 – Participants aged 18 or younger are being sought for a research study that could help your child and others who are experiencing chronic diarrhea and/or abdominal pain due to a possible deficiency in table sugar digestion. Learn more


September 28, 2014 – The U.S. Food and Drug Administration (FDA) approved an expanded use of the drug, Relistor, for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. 


June 30, 2014 – The U.S. Food and Drug Administration (FDA) has approved updated labeling for Gattex (teduglutide [rDNA origin]) for injection, to include long-term data from adult patients with Short Bowel Syndrome (SBS). Learn more


May 27, 2014 – An article published in the journal Therapeutic Advances in Gastroenterology reviewed data that examined the mechanisms by which bile acids can affect symptoms in chronic idiopathic constipation (CIC) and the role of the drug elobixibat in managing these symptoms. Learn more

Lubiprostone (Amitiza)

May 6, 2014 – A study published in the medical journal Pain Medicine concluded that lubiprostone effectively relieved symptoms of opioid-induced constipation (OIC) and associated signs and symptoms. Learn more


April 22, 2014 – Salix announced that their submission for the medication Relistor had been accepted for review by the European Medicines Agency. Their submission asks to allow the use of Relistor for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. The European Union already allows for the use of Relistor in patients with advanced illness.

Linaclotide (Linzess/Constella)

June 13, 2013 – Linaclotide is now available in Europe (branded as Costella in the EU) to treat irritable bowel syndrome with constipation (IBS-C)Learn more


September 6, 2011 – Oceana Therapeutics today announced the U.S. launch of Solesta, a significant new treatment option for patients with fecal (bowel) incontinence for whom conservative therapies have failed. Learn more


September 8, 2009 – The FDA has granted marketing approval for the drug metoclopramide (Metozolv) 5mg and 10 mg orally disintegrating tablets. The drug is indicated for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults and the treatment of symptomatic documented GERD in adults who do not respond to conventional therapy. Therapy should not exceed 12 weeks in duration. Important safety information should be discussed with your doctor. Learn more


January 30, 2009 – The U.S. Food and Drug Administration (FDA) today approved KAPIDEX™ (dexlansoprazole) delayed release capsules for the once-daily, oral treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE. KAPIDEX (30 mg and 60 mg) is the first proton pump inhibitor (PPI) with a Dual Delayed Release™ (DDR) formulation designed to provide two separate releases of medication. Learn more

Kapidex changed its name to Dexilant in April 2010. 



Last modified on January 29, 2016 at 02:05:15 PM